O. Faber

发表

The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

H. Mouridsen, L. Skovsted, O. Faber, 2009, Acta pharmacologica et toxicologica.

The metabolism of cyclophosphamide. Dose dependency and the effect of long‐term treatment with cyclophosphamide

H. Mouridsen, L. Skovsted, O. Faber, 1976, Cancer.

Glucose tolerance and B cell function in chronic alcoholism: its relation to hepatic histology and exocrine pancreatic function.

C. Hagen, O. Faber, J. Lindholm, 1983, Metabolism: clinical and experimental.

B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function

C. Hagen, T. Krarup, O. Faber, 1982, Diabetologia.

Intramolekulare Aromatenalkylierungen, 31. Mitt.: Synthese und Cyclisierung von 1,4‐Dimethyl‐3‐phenethyl‐1,2,3,6‐tetrahydropyridin. Intramolecular Alkylation of Aromatic Compounds, XXXI: Synthesis and Cyclisation of 1,4‐Dimethyl‐3‐phenyl‐ethyl‐1,2,3,6‐tetrahydropyridine

O. Faber, E. Reimann, 1994 .

The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.

H. Mouridsen, L. Skovsted, O. Faber, 1975, British journal of clinical pharmacology.

The biotransformation of cyclophosphamide in man: influence of prednisone.

H. Mouridsen, L. Skovsted, O. Faber, 2009, Acta pharmacologica et toxicologica.

The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate.

H. Mouridsen, E. Jacobsen, O. Faber, 2009, Acta pharmacologica et toxicologica.

No effect of bromocriptine in acromegaly: a controlled trial.

C. Hagen, O. Faber, J. Riishede, 1981, The New England journal of medicine.